Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705351 · ClinicalTrials.gov registry record · Phase 1
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
A Phase 1 study, sponsored by Providence Health & Services.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03705351 is a Phase 1 study that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 7 participants.
The verdict
NCT03705351, a Phase 1 study, was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temozolomide at a routine treatment dose and schedule.
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DEVICE Tumor Treating Fields
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2022-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03705351
The ClinicalTrials.gov registry entry for NCT03705351 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT03705351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03705351 about?
NCT03705351 is a clinical study titled "Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM". The study is an open-label pilot study in newly diagnosed glioblastoma patients following surgery. Eligible patients will receive treatment with tumor treating fields therapy using the Optune device starting less than 2 weeks prior to start of chemoradiation. Patients will receive radiation and temo...
What is the current status of trial NCT03705351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-12-02. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT03705351?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Tumor Treating Fields (DEVICE).
Who is sponsoring clinical trial NCT03705351?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.